Literature DB >> 24769780

Should guidelines for glycemic control of the critically ill be individualized?: Weighing the evidence from randomized and observational investigations.

James S Krinsley1.   

Abstract

The monitoring of blood glucose and treatment of hyperglycemia has been a standard of care in intensive care units since the publication of a single-center randomized controlled trial (RCT) of intensive insulin therapy in 2001 that demonstrated marked improvements in mortality. Professional societies created guidelines based on the results of this investigation, and revised them based on the results of a very small group of RCTs that followed. This commentary reviews the weight of evidence provided by the RCTs in comparison to the large body of evidence from observational studies regarding glycemic control of the critically ill, and suggests that the totality of evidence should be considered in the formulation of clinical practice paradigms.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24769780     DOI: 10.3810/hp.2014.04.1099

Source DB:  PubMed          Journal:  Hosp Pract (1995)        ISSN: 2154-8331


  3 in total

1.  Fifteen-minute Frequency of Glucose Measurements and the Use of Threshold Alarms: Impact on Mitigating Dysglycemia in Critically Ill Patients.

Authors:  Grant V Bochicchio; Stanley A Nasraway; Laura J Moore; Anthony P Furnary; Eden A Nohra; Kelly M Bochicchio; James C Boyd; David I Bruns; Irl B Hirsch; Jean-Charles Preiser; James S Krinsley
Journal:  J Diabetes Sci Technol       Date:  2019-11-19

2.  Comparison of Glycemic Control between Continuous Regular Insulin Infusion and Single-dose Subcutaneous Insulin Glargine Injection in Medical Critically Ill Patients.

Authors:  Rungsun Bhurayanontachai; Tharittamon Rattanaprapat; Chanon Kongkamol
Journal:  Indian J Crit Care Med       Date:  2018-03

3.  Glucose control in intensive care: usability, efficacy and safety of Space GlucoseControl in two medical European intensive care units.

Authors:  Karin Amrein; Norman Kachel; Heike Fries; Roman Hovorka; Thomas R Pieber; Johannes Plank; Urs Wenger; Barbara Lienhardt; Marco Maggiorini
Journal:  BMC Endocr Disord       Date:  2014-07-29       Impact factor: 2.763

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.